title: Animal models of fulminant hepatic failure: a critical evaluation.
abstract: Few conditions in medicine are more dramatic or more devastating than acute liver failure. Our understanding and treatment of this condition have been limited by the lack of satisfactory animal models. The most widely used models consist of surgical anhepatic and devascularization procedures and hepatotoxins, such as galactosamine and acetaminophen. Potential disadvantages with surgical models are their inability to recreate the inflammatory milieu that exists in acute liver failure and their reliance on surgical expertise. Models using hepatotoxins are free of such constraints. Galactosamine-induced hepatotoxicity is more predictable than acetaminophen, but its cost and lack of a human equivalent clinical syndrome has restricted its use. Acetaminophen-based models offer the greatest potential but have proven the most difficult to develop because of difficulties with reproducibility and refractory anemia. Although progress has been made, research must continue in this area to establish an animal model with minimal disadvantages that would accurately reflect the clinical syndrome seen in humans.
authors.affiliation: Liver Unit, Department of Internal Medicine, Royal Infirmary of Edinburgh, Scotland.
authors.forename: P N
authors.initials: PN
authors.lastname: Newsome
authors.forename: J N
authors.initials: JN
authors.lastname: Plevris
authors.forename: L J
authors.initials: LJ
authors.lastname: Nelson
authors.forename: P C
authors.initials: PC
authors.lastname: Hayes
mesh_terms: D000082:Acetaminophen; D018712:Analgesics, Non-Narcotic; D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D005688:Galactosamine; D006801:Humans; D017093:Liver Failure; D051379:Mice; D011817:Rabbits; D013552:Swine
chemical_list: D018712:Analgesics, Non-Narcotic; D000082:Acetaminophen; D005688:Galactosamine